5 Lessons From FDA's First Biosimilar Review

Law360, New York (January 8, 2015, 6:29 PM ET) -- Ringing endorsements by regulators and experts this week for Sandoz Inc.’s biosimilar Zarxio offer key insights into how the U.S. Food and Drug Administration will oversee Big Pharma’s next frontier, experts say.



Here are five lessons from the first-of-its-kind review:



Clear Road to Approval Emerges



Through guidance and closed-door meetings with drugmakers, the FDA in recent years has shed light on the evidence needed to prove that a proposed biosimilar sufficiently copies an existing biologic. But this week’s experience with Zarxio, the first product processed along...

To view the full article, register now.